TY  - JOUR
A1  - Hofgaard, Peter O.
A1  - Jodal, Henriette C.
A1  - Bommert, Kurt
A1  - Huard, Bertrand
A1  - Caers, Jo
A1  - Carlsen, Harald
A1  - Schwarzer, Rolf
A1  - Schünemann, Nicole
A1  - Jundt, Franziska
A1  - Lindeberg, Mona M.
A1  - Bogen, Bjarne
T1  - A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease
JF  - PLoS One
N2  - Multiple myeloma (MM) is a lethal human cancer characterized by a clonal expansion of malignant plasma cells in bone marrow. Mouse models of human MM are technically challenging and do not always recapitulate human disease. Therefore, new mouse models for MM are needed. Mineral-oil induced plasmacytomas (MOPC) develop in the peritoneal cavity of oil-injected BALB/c mice. However, MOPC typically grow extramedullary and are considered poor models of human MM. Here we describe an in vivo-selected MOPC315 variant, called MOPC315.BM, which can be maintained in vitro. When injected i.v. into BALB/c mice, MOPC315.BM cells exhibit tropism for bone marrow. As few as 10\(^4\) MOPC315.BM cells injected i.v. induced paraplegia, a sign of spinal cord compression, in all mice within 3-4 weeks. MOPC315.BM cells were stably transfected with either firefly luciferase (MOPC315.BM.Luc) or DsRed (MOPC315.BM.DsRed) for studies using noninvasive imaging. MOPC315.BM.Luc cells were detected in the tibiofemoral region already 1 hour after i.v. injection. Bone foci developed progressively, and as of day 5, MM cells were detected in multiple sites in the axial skeleton. Additionally, the spleen (a hematopoietic organ in the mouse) was invariably affected. Luminescent signals correlated with serum myeloma protein concentration, allowing for easy tracking of tumor load with noninvasive imaging. Affected mice developed osteolytic lesions. The MOPC315.BM model employs a common strain of immunocompetent mice (BALB/c) and replicates many characteristics of human MM. The model should be suitable for studies of bone marrow tropism, development of osteolytic lesions, drug testing, and immunotherapy in MM.
KW  - resistance
KW  - CD4(+) T-cells
KW  - tumor specific antigen
KW  - plasma cells
KW  - B cell
KW  - C57BL/KALWRIJ mouse
KW  - bone disease
KW  - scid mice
KW  - idiotype
KW  - differentiation
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-131117
VL  - 7
IS  - 12
ER  - 
TY  - JOUR
A1  - Ludwig, Heinz
A1  - Delforge, Michel
A1  - Facon, Thierry
A1  - Einsele, Hermann
A1  - Gay, Francesca
A1  - Moreau, Philippe
A1  - Avet-Loiseau, Hervé
A1  - Boccadoro, Mario
A1  - Hajek, Roman
A1  - Mohty, Mohamad
A1  - Cavo, Michele
A1  - Dimopoulos, Meletios A
A1  - San-Miguel, Jesús F
A1  - Terpos, Evangelos
A1  - Zweegman, Sonja
A1  - Garderet, Laurent
A1  - Mateos, María-Victoria
A1  - Cook, Gordon
A1  - Leleu, Xavier
A1  - Goldschmidt, Hartmut
A1  - Jackson, Graham
A1  - Kaiser, Martin
A1  - Weisel, Katja
A1  - van de Donk, Niels W. C. J.
A1  - Waage, Anders
A1  - Beksac, Meral
A1  - Mellqvist, Ulf H.
A1  - Engelhardt, Monika
A1  - Caers, Jo
A1  - Driessen, Christoph
A1  - Bladé, Joan
A1  - Sonneveld, Pieter
T1  - Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
JF  - Leukemia
N2  - During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.
KW  - disease prevention
KW  - myeloma
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-237338
VL  - 32
ER  - 
TY  - JOUR
A1  - Musto, Pellegrino
A1  - Engelhardt, Monika
A1  - Caers, Jo
A1  - Bolli, Niccolo'
A1  - Kaiser, Martin
A1  - van de Donk, Niels
A1  - Terpos, Evangelos
A1  - Broijl, Annemiek
A1  - de Larrea, Carlos Fernández
A1  - Gay, Francesca
A1  - Goldschmidt, Hartmut
A1  - Hajek, Roman
A1  - Vangsted, Annette Juul
A1  - Zamagni, Elena
A1  - Zweegman, Sonja
A1  - Cavo, Michele
A1  - Dimopoulos, Meletios
A1  - Einsele, Hermann
A1  - Ludwig, Heinz
A1  - Barosi, Giovanni
A1  - Boccadoro, Mario
A1  - Mateos, Maria-Victoria
A1  - Sonneveld, Pieter
A1  - San Miguel, Jesus
T1  - 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
JF  - Haematologica
N2  - According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, bone marrow plasma cell infiltration >10% and <60%, and absence of any myeloma-defining event. Active multiple myeloma is preceded by SMM, with a median time to progression of approximately 5 years. Cases of SMM range from the extremes of “monoclonal gammopathy of undetermined significance-like”, in which patients never progress during their lifetimes, to “early multiple myeloma”, in which transformation into symptomatic disease, based on genomic evolution, may be rapid and devastating. Such a “split personality” makes the prognosis and management of individual patients challenging, particularly with regard to the identification and possible early treatment of high-risk SMM. Outside of clinical trials, the conventional approach to SMM generally remains close observation until progression to active multiple myeloma. However, two prospective, randomized trials have recently demonstrated a significant clinical benefit in terms of time to progression, and of overall survival in one of the two studies, for some patients with higher-risk SMM treated with lenalidomide ± dexamethasone, raising the question of whether such an approach should be considered a new standard of care. In this paper, experts from the European Myeloma Network describe current biological and clinical knowledge on SMM, focusing on novel insights into its molecular pathogenesis, new prognostic scoring systems proposed to identify SMM patients at higher risk of early transformation, and updated results of completed or ongoing clinical trials. Finally, some practical recommendations for the real-life management of these patients, based on Delphi consensus methodology, are provided.
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-371372
VL  - 106
ER  -